Hemostasis, Thrombosis, Antithrombotic Therapy, and Thrombolysis in Vascular Practice
Hemostasis, thrombosis, antithrombotic therapy, and thrombolysis as competing bedside risks in the vascular patient. The chapter frames antiplatelet and anticoagulant decisions, periprocedural management, and selective thrombolysis around the dominant clinical risk rather than around isolated laboratory pathways.
Consult corner: A bedside consult-style discussion focused on what the clinician should decide next and what not to overinterpret.
General medical education, not patient-specific advice.
Choose the hostsAntithrombotic selection principles
Antithrombotic management matches therapeutic intensity to the distinct risks of arterial prevention and venous treatment. Peripheral artery disease (PAD) is managed with antiplatelet therapy or dual-pathway inhibition to reduce major adverse cardiovascular events (MACE) and major adverse limb events (MALE) . Venous thromboembolism (VTE) relies on full-intensity anticoagulation, with thrombolysis reserved for defined hemodynamic or limb threats . Full-intensity oral anticoagulation is not used for PAD risk reduction unless a separate indication, such as atrial fibrillation or VTE, exists .
Bleeding risk informs every therapy escalation. Structured bleeding-history assessment using the ISTH/SSC bleeding assessment tool supplements laboratory hemostasis testing, identifying lifelong bleeding phenotypes that casual history misses . In clinical trials, bleeding outcomes are standardized by the ISTH major bleeding definition for non-surgical patients, providing the baseline for comparing regimen safety .
Antiplatelet therapy and dual-pathway inhibition
Single antiplatelet therapy is the baseline for symptomatic PAD, using either clopidogrel 75 mg daily or aspirin 75 to 325 mg daily . In CAPRIE, clopidogrel 75 mg daily reduced the annual rate of ischemic stroke, myocardial infarction, or vascular death compared with aspirin 325 mg daily in patients with atherosclerotic vascular disease (5.32% vs 5.83%; an 8.7% relative-risk reduction) . Ticagrelor 90 mg twice daily is not superior to clopidogrel 75 mg daily for symptomatic PAD; EUCLID demonstrated equivalent event rates (10.8% vs 10.6%) and identical major bleeding rates (1.6%) .
After endovascular lower-extremity revascularization, dual antiplatelet therapy (DAPT) combining a P2Y12 antagonist with low-dose aspirin is used for 1 to 6 months to protect the treated segment . Historical trials of long-term DAPT in broad populations, such as CHARISMA, do not override this targeted procedural indication .
Dual-pathway inhibition combines low-dose rivaroxaban 2.5 mg twice daily with low-dose aspirin and is indicated for stable atherosclerotic disease and post-revascularization PAD when bleeding risk is acceptable .
- Post-revascularization: In VOYAGER PAD, the combination reduced the 3-year limb and cardiovascular composite compared with aspirin alone (17.3% vs 19.9%, HR 0.85). This benefit is balanced against an increase in TIMI major bleeding (2.65% vs 1.87%) and ISTH major bleeding (5.94% vs 4.06%) .
- Stable disease: In COMPASS, the combination reduced cardiovascular death, stroke, or myocardial infarction (4.1% vs 5.4%, HR 0.76), but increased major bleeding (3.1% vs 1.9%, HR 1.70) without increasing intracranial or fatal bleeding .
- PAD subgroup: Among the COMPASS PAD cohort (7470 patients), cardiovascular events were reduced (5% vs 7%) and major adverse limb events decreased (1% vs 2%), alongside an increase in mainly gastrointestinal major bleeding (3% vs 2%) .
Arterial antithrombotic regimens for PAD
| Scenario | Regimen | Clinical outcome | Citation |
|---|---|---|---|
| Symptomatic PAD | Single antiplatelet therapy (clopidogrel 75 mg or aspirin 75 to 325 mg daily) | Baseline reduction of MACE and MALE | |
| Post-endovascular revascularization | DAPT (P2Y12 antagonist plus low-dose aspirin) for 1 to 6 months | Prevents early procedural-segment thrombosis | |
| Post-revascularization, acceptable bleeding risk | Dual-pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin) | Reduces 3-year limb/cardiovascular events; increases major bleeding | |
| Stable PAD, acceptable bleeding risk | Dual-pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin) | Reduces MACE and MALE; increases major bleeding |
- Regimen
- Single antiplatelet therapy (clopidogrel 75 mg or aspirin 75 to 325 mg daily)
- Clinical outcome
- Baseline reduction of MACE and MALE
- Citation
- Regimen
- DAPT (P2Y12 antagonist plus low-dose aspirin) for 1 to 6 months
- Clinical outcome
- Prevents early procedural-segment thrombosis
- Citation
- Regimen
- Dual-pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin)
- Clinical outcome
- Reduces 3-year limb/cardiovascular events; increases major bleeding
- Citation
- Regimen
- Dual-pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin)
- Clinical outcome
- Reduces MACE and MALE; increases major bleeding
- Citation
Putting the decision in order
- Establish the indication: primary prevention, symptomatic atherosclerotic disease, post-revascularization, or a distinct anticoagulation indication such as atrial fibrillation or venous thromboembolism.
- Choose the base regimen for that indication: single antiplatelet therapy as the baseline, dual-pathway inhibition or time-limited DAPT where indicated, and therapeutic anticoagulation only for a distinct indication, not added to antiplatelet therapy without cause .
- Layer duration and bleeding-risk modifiers onto that regimen.
- Plan periprocedural interruption and reversal.
Venous thromboembolism anticoagulation phases
Anticoagulation for VTE is structured in defined phases: initial management covering the first 5 to 21 days, primary treatment continuing for a minimum of 3 to 6 months, and secondary prevention consisting of indefinite continuation with regular reassessment .
Direct oral anticoagulants (DOACs) are standard VTE comparators, supported by a family of landmark trials. AMPLIFY demonstrated that apixaban (10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) achieved noninferiority for recurrent VTE or VTE-related death (2.3% vs 2.7%) with significantly lower major bleeding (0.6% vs 1.8%) compared with conventional enoxaparin and warfarin therapy . Analogous evidence supports rivaroxaban (EINSTEIN-PE), edoxaban (Hokusai-VTE), and dabigatran (RE-COVER) for acute VTE management . Final drug selection is tailored to renal function, pregnancy status, malignancy, drug interactions, and antiphospholipid syndrome.
Thrombolysis selection in venous disease
Thrombolysis exposes the patient to systemic bleeding risk and is restricted to defined criteria rather than routine anatomic burden. For pulmonary embolism, thrombolytic therapy is indicated when accompanied by hemodynamic compromise .
For deep vein thrombosis (DVT), thrombolysis is indicated for limb-threatening presentations such as phlegmasia cerulea dolens, and for selected younger patients with low bleeding risk and symptomatic iliac or common femoral DVT. Thrombus removal is rarely indicated for DVT limited below the common femoral vein .
The evidence for venous thrombus removal balances moderate symptom relief against early bleeding:
- ATTRACT: In acute proximal DVT, pharmacomechanical thrombolysis did not reduce overall post-thrombotic syndrome from 6 to 24 months (47% vs 48%) and increased major bleeding within 10 days (1.7% vs 0.3%). It did reduce the rate of moderate-to-severe post-thrombotic syndrome (18% vs 24%) .
- CaVenT: Provides the landmark comparator for additional catheter-directed thrombolysis in acute iliofemoral DVT .
Thrombolysis thresholds and trial outcomes
- Intervention threshold
- Hemodynamic compromise
- Clinical outcome or trial finding
- Reperfusion indicated to resolve systemic instability
CitationAcute deep vein thrombosis
- Intervention threshold
- Phlegmasia cerulea dolens or selected symptomatic iliofemoral DVT
- Clinical outcome or trial finding
- Lysis indicated for limb threat or targeted symptom relief
CitationProximal DVT (ATTRACT trial)
- Intervention threshold
- Pharmacomechanical thrombolysis
- Clinical outcome or trial finding
- No reduction in overall PTS (47% vs 48%); increased 10-day major bleeding (1.7% vs 0.3%)
CitationIliofemoral DVT (CaVenT trial)
- Intervention threshold
- Catheter-directed thrombolysis
- Clinical outcome or trial finding
- Landmark comparator for iliofemoral thrombus removal
Citation
Peri-procedural interruption and bridging
Peri-procedural antithrombotic interruption balances operative hemostasis against the exact thrombotic indication. PAUSE defines contemporary management for patients with atrial fibrillation receiving apixaban, dabigatran, or rivaroxaban who undergo elective procedures, providing structured interruption without routine bridging . Under PAUSE, apixaban and rivaroxaban, and dabigatran when CrCl is 50 mL/min or higher, are omitted 1 day before a low-bleeding-risk procedure and 2 days before a high-bleeding-risk procedure; dabigatran with CrCl below 50 mL/min is omitted 2 days before low-risk and 4 days before high-risk procedures. No heparin bridging and no preoperative coagulation testing. Anticoagulation resumes 1 day after low-risk procedures and 2 to 3 days after high-risk procedures. This standardized schedule produced 30-day major bleeding under 2% and arterial thromboembolism at or below 0.6%.
Bridging therapy is not a default response to interruption. In BRIDGE, omitting bridging for warfarin-treated atrial fibrillation patients undergoing elective procedures was noninferior to low-molecular-weight heparin bridging for thromboembolism prevention and resulted in less major bleeding . In BRIDGE, warfarin was withheld about 5 days before the elective procedure to let the INR normalize toward a target below 1.5 at surgery, then resumed within 24 hours once hemostasis was secured . Bridging is reserved for specific high-risk indications. These are any mechanical mitral valve, a caged-ball or tilting-disc mechanical aortic valve, stroke, TIA, or venous thromboembolism within the prior 3 months, and atrial fibrillation with a high CHA2DS2-VASc or CHADS2 score (CHADS2 5 to 6) or rheumatic valvular disease. Non-valvular atrial fibrillation at lower risk is not bridged. Postoperative resumption requires securing hemostasis before returning to the original therapy phase . Interruption timing is set by the agent half-life and the procedure bleeding risk. For life-threatening bleeding or urgent surgery, reverse dabigatran with idarucizumab, factor Xa inhibitors with andexanet alfa or four-factor prothrombin complex concentrate, and unfractionated heparin with protamine .
Areas of controversy
- Net benefit of dual-pathway inhibition: The absolute reduction in major adverse cardiovascular and limb events with low-dose rivaroxaban plus aspirin is established, but the concurrent increase in ISTH and TIMI major bleeding creates varied interpretations of net clinical benefit across different baseline bleeding risks .
- Post-endovascular DAPT duration: While guidelines support a 1 to 6 month window for dual antiplatelet therapy after endovascular PAD revascularization, the exact duration remains empirical and centre-driven, varying by the device deployed and the anatomic segment treated .
- Thrombus removal in proximal DVT: The role of early thrombus removal remains debated; the reduction in moderate-to-severe post-thrombotic syndrome must be weighed against the failure to prevent overall post-thrombotic syndrome and the documented increase in early major bleeding .
References
- 1.
- 2.ESVS 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases. 2023.DOI publisher routeClinical practice guideline2023
ESVS 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases. 2023. doi:10.1016/j.ejvs.2023.03.042.
- 3.American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. 2020.PubMed-indexed articleClinical practice guideline2020
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. 2020. doi:10.1182/bloodadvances.2020001830.
- 4.Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382(21):1994-2004.PubMed-indexed articleRandomized controlled trial2020
Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382(21):1994-2004. doi:10.1056/NEJMoa2000052. PMID:32222135.
- 5.
- 6.ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. 2010.PubMed-indexed article2010
ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. 2010. doi:10.1111/j.1538-7836.2010.03975.x.
- 7.Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. 2005.PubMed-indexed article2005
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. 2005. doi:10.1111/j.1538-7836.2005.01204.x.
- 8.A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). 1996.PubMed-indexed articleRandomized controlled trial1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). 1996. doi:10.1016/s0140-6736(96)09457-3.
- 9.
- 10.
- 11.
- 12.
- 13.Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. 2017.PubMed-indexed articleClinical practice guideline2017
Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. 2017. doi:10.1093/eurheartj/ehx003.
- 14.
- 15.
- 16.
- 17.
- 18.2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). 2019.PubMed-indexed articleClinical practice guideline2019
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). 2019. doi:10.1093/eurheartj/ehz405.
- 19.
- 20.Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. 2012.PubMed-indexed articleRandomized controlled trial2012
Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. 2012. doi:10.1016/s0140-6736(11)61753-4.
- 21.Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. 2019.PubMed-indexed articleRegistry / cohort2019
Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. 2019. doi:10.1001/jamainternmed.2019.2431.
- 22.
- 23.Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207-e243.PubMed-indexed article2022
Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025. PMID:35964704.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.